"Triple negative breast cancer represents only 10-15% of all breast cancer, but is a particularly aggressive form of the disease. Some women with triple negative breast cancer do very well and have an excellent outcome, probably because their cancer is very sensitive to chemotherapy. In other women, however, the cancer is resistant to chemotherapy and will often spread to other organs. Unfortunately, many of these women have a relatively short life expectancy.
Our group at Dana-Farber Cancer Institute is dedicated to finding new treatment approaches for triple negative breast cancer. We are tackling this problem by gaining a better understanding of the genetic and biologic features of triple negative breast cancer. We are also testing a variety of new treatments, all of which have promise for women with the disease. Our approach is to bring together groups of clinicians and scientists to focus on the problem. and through these collaborations we hope to make great progress. As both a clinician and researcher, I believe we will be in a very different place with triple negative breast cancer in 10 years than we are today."
- Eric P. Winer, M.D